• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Real-World Evidence in EU Medicines Regulation: Enabling Use and Establishing Value.

作者信息

Arlett Peter, Kjaer Jesper, Broich Karl, Cooke Emer

机构信息

European Medicines Agency, Amsterdam, Netherlands.

Danish Medicines Agency, Copenhagen, Denmark.

出版信息

Clin Pharmacol Ther. 2022 Jan;111(1):21-23. doi: 10.1002/cpt.2479. Epub 2021 Nov 19.

DOI:10.1002/cpt.2479
PMID:34797920
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9299492/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7af1/9299492/85e0552f47bd/CPT-111-21-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7af1/9299492/85e0552f47bd/CPT-111-21-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7af1/9299492/85e0552f47bd/CPT-111-21-g001.jpg

相似文献

1
Real-World Evidence in EU Medicines Regulation: Enabling Use and Establishing Value.欧盟药品监管中的真实世界证据：促进使用与确立价值
Clin Pharmacol Ther. 2022 Jan;111(1):21-23. doi: 10.1002/cpt.2479. Epub 2021 Nov 19.
2
Medicines to remain with European Commission health directorate.药品将留在欧盟委员会卫生司。
BMJ. 2014 Oct 29;349:g6514. doi: 10.1136/bmj.g6514.
3
Future of the European Union regulatory network in the context of the uptake of new medicines.新药品应用背景下欧盟监管网络的未来。
Br J Clin Pharmacol. 2013 Jul;76(1):1-6. doi: 10.1111/j.1365-2125.2012.04476.x.
4
Statisticians in European regulatory agencies.欧洲监管机构的统计学家。
Pharm Stat. 2009 Oct-Dec;8(4):259-63. doi: 10.1002/pst.367.
5
Marketing Authorization Applications Made to the European Medicines Agency in 2018-2019: What was the Contribution of Real-World Evidence?2018-2019 年向欧洲药品管理局提交的营销授权申请：真实世界证据的贡献是什么？
Clin Pharmacol Ther. 2022 Jan;111(1):90-97. doi: 10.1002/cpt.2461. Epub 2021 Nov 13.
6
Use of real-world evidence in postmarketing medicines regulation in the European Union: a systematic assessment of European Medicines Agency referrals 2013-2017.利用真实世界证据进行欧盟上市后药品监管：2013-2017 年欧洲药品管理局转介的系统评估。
BMJ Open. 2019 Oct 28;9(10):e028133. doi: 10.1136/bmjopen-2018-028133.
7
Use of Real-World Data and Evidence in Drug Development of Medicinal Products Centrally Authorized in Europe in 2018-2019.2018-2019 年在欧洲集中授权药物的药品开发中使用真实世界数据和证据。
Clin Pharmacol Ther. 2022 Jan;111(1):310-320. doi: 10.1002/cpt.2462. Epub 2021 Nov 16.
8
The European Medicines Agency facilitates access to medicines in low- and middle-income countries.欧洲药品管理局为中低收入国家提供药品准入渠道。
Expert Rev Clin Pharmacol. 2020 Mar;13(3):321-325. doi: 10.1080/17512433.2020.1724782. Epub 2020 Feb 13.
9
Prohibiting or 'managing' conflict of interest? A review of policies and procedures in three European drug regulation agencies.禁止还是“管理”利益冲突？对三个欧洲药品监管机构的政策和程序的审查。
Soc Sci Med. 2010 Mar;70(5):643-7. doi: 10.1016/j.socscimed.2009.09.002. Epub 2009 Sep 24.
10
Statistical resource needs to be increased in the European regulatory agencies.欧洲监管机构需要增加统计资源。
Pharm Stat. 2011 Mar-Apr;10(2):87-8. doi: 10.1002/pst.416.

引用本文的文献

1
Augmenting Treatment Arms With External Data Through Propensity-Score Weighted Power Priors: An Application in Expanded Access.通过倾向得分加权功率先验使用外部数据增强治疗组：在扩大准入中的应用
Stat Med. 2025 Aug;44(18-19):e70168. doi: 10.1002/sim.70168.
2
Pharmacovigilance in Cell and Gene Therapy: Evolving Challenges in Risk Management and Long-Term Follow-Up.细胞与基因治疗中的药物警戒：风险管理与长期随访中不断演变的挑战
Drug Saf. 2025 Aug 9. doi: 10.1007/s40264-025-01596-9.
3
Harnessing digital health technologies and real-world evidence to enhance clinical research and patient outcomes.

本文引用的文献

1
Marketing Authorization Applications Made to the European Medicines Agency in 2018-2019: What was the Contribution of Real-World Evidence?2018-2019 年向欧洲药品管理局提交的营销授权申请：真实世界证据的贡献是什么？
Clin Pharmacol Ther. 2022 Jan;111(1):90-97. doi: 10.1002/cpt.2461. Epub 2021 Nov 13.
2
Randomized Controlled Trials Versus Real World Evidence: Neither Magic Nor Myth.随机对照试验与真实世界证据：非魔亦非幻。
Clin Pharmacol Ther. 2021 May;109(5):1212-1218. doi: 10.1002/cpt.2083. Epub 2020 Nov 12.
3
Considerations for pharmacoepidemiological analyses in the SARS-CoV-2 pandemic.
利用数字健康技术和真实世界证据来加强临床研究并改善患者治疗效果。
Digit Health. 2025 Jul 23;11:20552076251362097. doi: 10.1177/20552076251362097. eCollection 2025 Jan-Dec.
4
[More pragmatic randomized studies with a focus on registry-based trials].[更多注重基于注册登记的试验的务实随机研究]
Pravent Gesundh. 2022 Aug 22:1-9. doi: 10.1007/s11553-022-00974-w.
5
Optimizing Patient Registries for Regulatory Decision Making - Key Learnings From an HMA/EMA Multistakeholder Workshop.优化用于监管决策的患者登记系统——来自HMA/EMA多利益相关方研讨会的关键经验教训
Clin Pharmacol Ther. 2025 Sep;118(3):551-560. doi: 10.1002/cpt.3733. Epub 2025 Jun 2.
6
The role and value of real-world evidence in health technology decision-making in France, Germany, Italy, Spain, and the UK: insights on external control arms.真实世界证据在法国、德国、意大利、西班牙和英国卫生技术决策中的作用与价值：关于外部对照臂的见解
Int J Technol Assess Health Care. 2025 Apr 22;41(1):e25. doi: 10.1017/S0266462324004720.
7
Development and Assessment of a Patient-Reported Outcome Instrument for Gender-Affirming Care.一种用于性别肯定治疗的患者报告结局工具的开发与评估
JAMA Netw Open. 2025 Apr 1;8(4):e254708. doi: 10.1001/jamanetworkopen.2025.4708.
8
Analysis of Real-World Progression and Insufficient Response Variables and Related Endpoints Among Patients with Non-Hodgkin Lymphoma.非霍奇金淋巴瘤患者的真实世界病情进展、反应不足变量及相关终点分析
Adv Ther. 2025 Apr;42(4):1979-1993. doi: 10.1007/s12325-025-03143-5. Epub 2025 Mar 3.
9
The EU project Real4Reg: unlocking real-world data with AI.欧盟项目Real4Reg：利用人工智能解锁真实世界数据。
Health Res Policy Syst. 2025 Feb 27;23(1):27. doi: 10.1186/s12961-025-01287-y.
10
Clinical Evidence 2030.临床证据2030
Clin Pharmacol Ther. 2025 Apr;117(4):884-886. doi: 10.1002/cpt.3596. Epub 2025 Feb 14.
2019冠状病毒病大流行期间药物流行病学分析的考量因素
Pharmacoepidemiol Drug Saf. 2020 Aug;29(8):825-831. doi: 10.1002/pds.5029. Epub 2020 May 21.
4
Real-World Data for Regulatory Decision Making: Challenges and Possible Solutions for Europe.用于监管决策的真实世界数据：欧洲面临的挑战与可能的解决方案
Clin Pharmacol Ther. 2019 Jul;106(1):36-39. doi: 10.1002/cpt.1426. Epub 2019 Apr 10.